跳至主要内容
临床试验/ITMCTR2100004759
ITMCTR2100004759招募中1 期

Professor Hua Bao-jin's Clinical Proven Prescription for Prevention and Treatment of Recurrence and Metastasis of Limited Stage Small Cell Lung Cancer: a Non-Randomized Concurrent Controlled Clinical Trial in a Real World Study

Guang'anmen Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • 1. Aged 18-75 years.
  • 2. Patients with limited-stage SCLC who have a clear pathological diagnosis and have received first-line treatment (standard radiotherapy and chemotherapy regimens).
  • 3. The expected survival time is >= 6 months.
  • 4. The ECOG score of physical strength is 0-2 points.
  • 5. Volunteer to participate in this study and sign an informed consent form.
  • 6. Chemotherapy >= 2 cycles, and the curative effect is evaluated as SD, PR or CR.

排除标准

  • 1. Combined with serious diseases such as heart, liver, kidney and hematopoietic system.
  • 2. Patients who are known to be allergic to the study medication.
  • 3. Children, pregnant women, psychiatric patients and patients suffering from other malignant tumors.
  • 4. Patients who are undergoing other drug trials.
  • 5. Patients who have completed lung cancer surgery.
  • 6. Patients whose curative effect is evaluated as PD after chemotherapy.

研究者

相似试验